Purpose of this Study
The treatment will last for 12 months. People in the study will get shots of a medicine called omalizumab. Some will get the shots every month, and others will get them every two weeks. At each visit, they will answer questions on forms. Blood will be taken at the first visit and the last visit.
Who Can Participate?
Eligibility
People in this study must be at least 40 years old and have smoked for more than 10 years. They need to have a lung disease called COPD and already be using certain inhaled medicines. They must have a high score on a breathing test or have had at least one bad flare-up in the past year. Women who can have babies must have a negative pregnancy test before starting, and both men and women must agree to use birth control during the study. Their lung test results must show reduced breathing ability. They also need to have an allergy to things like cats, dogs, mice, cockroaches, or dust mites, and still be exposed to that allergen at home.
Age Range
40-110
Sex/Genders
Male (cisgender)
Female (cisgender)
Looking for Healthy Participants
No
What is Involved?
Description
The goal of this study is to find out if shots of a medicine called omalizumab, also known as Xolair, can lower the number of times people have bad flare-ups of their illness each year.
Locations
Other
Visit Timing
Weekdays
Compensation
Yes
Spanish Materials Available
No
Study Details
Full Title
Clinical Trials of Omalizumab for Allergen Sensitized and Exposed Individuals with COPD
Study Website
Principal Investigator
Loretta
Que
Protocol Number
PRO00119272
NCT ID
NCT07059091
Phase
II
Enrollment Status
Pending Open to Enrollment